. 2016 Dec 9;12(2):332–345. doi: 10.2215/CJN.05000516

Table 3.

Therapy procedures for children, modified by KDIGO 2012 (43), Prof. Arvind Bagga, and authors’ clinical experience

Therapy	United States 2009	India 2008	France 2008	KDIGO 2012	Italy 2016 (SINePe Recommendations in Preparation)
PDN at onset	2 mg/kg per d, 6 wk	2 mg/kg per d, 6 wk	60 mg/m² per d, 4 wk	60 mg/m² per d (or 2 mg/kg per d), 4–6 wk	60 mg/m² per d, 6 wk
	1.5 mg/kg every other d	1.5 mg/kg every other d	60 mg/m² every other d	40 mg/m² every other d (or 1.5 mg/kg every other d), 2–5 mo, taper	40 mg/m² every other d, 6 wk
	6 wk, no taper	6 wk, no taper	8 wk, taper	Minimum duration 12 wk	No taper
	Duration 12 wk	Duration 12 wk	Duration 18 wk		Duration 12 wk
PDN in relapse (first relapses, NRNS)	2 mg/kg per d until 3 d after remission; 1.5 mg/kg every other d	2 mg/kg per d until 3 d after remission	60 mg/m² per d until 6 d after remission	60 mg/m² per d (or 2 mg/kg per d) until 3 d after remission	60 mg/m² per d until 5 d after remission
	4 wk, no taper	1.5 mg/kg every other d, 4 wk, no taper	60 mg/m² every other d, 4 wk, taper	40 mg/m² every other d (or 1.5 mg/kg every other d), 4 wk	40 mg/m² every other d, 4 wk
	4 wk, no taper	1.5 mg/kg every other d, 4 wk, no taper	60 mg/m² every other d, 4 wk, taper	No taper	No taper
Long-term PDN (FRNS or SDNS)	2 mg/kg per d until 3 d after remission	2 mg/kg per d until 3 d after remission	60 mg/m² per d until 6 d after remission	60 mg/m² per d (or 2 mg/kg per d) until 3 d after remission	Not yet available
	1.2 mg/kg every other d, 4 wk	1.2 mg/kg every other d, 4 wk	60 mg/m² every other d, 4 wk	40 mg/m² every other d (or 1.5 mg/kg every other d)
	Taper by 0.5 mg/kg every other d over 2 mo	Taper by 0.5–0.7 mg/kg every other d	Taper by 15 mg/m² every other d, every 2 wk up to 15 mg/m² every other d, continue for 12–18 mo	Taper over ≥3 mo
		Continue for 9–18 mo		Lowest every other d or daily dose to maintain remission
Steroid-sparing agents (FRNS or SDNS)	FRNS: CPA 12 wk	Lev 1–2 yr	Lev	CPA 8–12 wk	Not yet available
	MMF 1–2 yr	CPA 12 wk	CPA	Chlorambucil 8 wk
	CsA/TAC 2–5 yr	CsA/TAC 1–2 yr	CsA	Lev>1 yr
	SDNS: CsA/TAC	MMF 1–2 yr	MMF	CsA/TAC>1 yr
	MMF			MMF>1 yr
	CPA			Rituximab

KDIGO, Kidney Disease Improving Global Outcomes; SINePe, Società Italiana Nefrologia Pediatrica; PDN, prednisone; NRNS, nonrelapsing nephrotic syndrome; FRNS, frequently relapsing nephrotic syndrome; SDNS, steroid-dependent nephrotic syndrome; CPA, cyclophosphamide; Lev, levamisole; MMF, mofetil mycophenolate; CsA, cyclosporine A; TAC, tacrolimus.